# Ranolazine, Ethnicity and the Metabolic Syndrome

Study · id `cardio:ct-nct01304095` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01304095](<https://clinicaltrials.gov/study/NCT01304095>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01304095

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

## Technical summary

Registry record NCT01304095. Randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2013-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT01304095, source copy `cardio:ctgov-nct01304095-2013-07-11`, retrieved 2026-10-26)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01304095, source copy `cardio:ctgov-nct01304095-2013-07-11`, retrieved 2026-10-26)
- Primary completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01304095, source copy `cardio:ctgov-nct01304095-2013-07-11`, retrieved 2026-10-26)
- Completion: 2013-11 (anticipated) (ClinicalTrials.gov record NCT01304095, source copy `cardio:ctgov-nct01304095-2013-07-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01304095, source copy `cardio:ctgov-nct01304095-2013-07-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01304095-2013-07-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ranolazine, Ethnicity and the Metabolic Syndrome
- Acronym: REMS
- Condition: Coronary Artery Disease
- Condition: Angina
- Condition: Metabolic Syndrome
- Intervention (Drug): Ranolazine
- Lead sponsor: Atlanta Heart Specialists, LLC
- Lead sponsor class: OTHER
- Collaborator: Gilead Sciences
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry lists this organization as a collaborator: Gilead Sciences (`cardio:org-gilead-sciences`)

## Provenance

Content hash: 2eee1cc3246e5210f7f2d96fe4b925604e4652c8c776267ebc4cdd72b8bda665
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
